Assessment of genomic instability in normal and diabetic rats treated with metformin

Chemico-Biological Interactions

Volumn 180, Issue 2, 2009, Pages 296-304

  Attia, S M ^a,b   Helal, G K ^a,b   Alhaider, A A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Al Azhar University   (Egypt)

Author keywords

Carcinogenicity; Chromosomal aberrations; Diabetes; Metformin; Micronuclei; Oxidative stress

Indexed keywords

GLUTATHIONE; METFORMIN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; CHROMOSOME ABERRATION; CYTOTOXICITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; GENOMIC INSTABILITY; GENOTOXICITY; GERM CELL; HYPERGLYCEMIA; LIPID PEROXIDATION; MALE; MICRONUCLEUS TEST; MITOSIS INHIBITION; NONHUMAN; OXIDATIVE STRESS; RAT; SINGLE DRUG DOSE; SPERMATOZOON ABNORMALITY; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY;

ANIMALS; CHROMOSOME ABERRATIONS; DIABETES MELLITUS, EXPERIMENTAL; DRUG ADMINISTRATION SCHEDULE; GENOMIC INSTABILITY; GLUTATHIONE; HYPOGLYCEMIC AGENTS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; METFORMIN; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MITOSIS; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SPERM MOTILITY; SPERMATOZOA;

ANIMALIA; MAMMALIA; RATTUS;

EID: 67349279599     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.03.001     Document Type: Article

References (69)

1. Clark S.F. The biochemistry of antioxidants revisited. Nutr. Clin. Pract. 17 (2002) 5-17
2. Poulsen H.E. Oxidative DNA modifications. Exp. Toxicol. Pathol. 57 Suppl. 1 (2005) 161-169
3. Dizdaroglu M., Jaruga P., Birincioglu M., and Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic. Biol. Med. 32 (2002) 1102-1115
4. Osawa T., and Kato Y. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann. N.Y. Acad. Sci. 1043 (2005) 440-451
5. Nuttal S.L., Dunne F., Kendall M.J., and Martin U. Age-independent oxidative stress in elderly patients with non-insulin-dependent diabetes mellitus. QJM 92 (1999) 33-38
6. Cousineau I., Abaji C., and Belmaaza A. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res. 15 (2005) 11384-11391
7. Singh P., Jain A., and Kaur G. Impact of hypoglycemia and diabetes on CNS: correlation of mitochondrial oxidative stress with DNA damage. Mol. Cell. Biochem. 260 (2004) 153-159
8. Blasiak J., Arabski M., Krupa R., Wozniak K., Zadrozny M., Kasznicki J., Zurawska M., and Drzewoski J. DNA damage and repair in type 2 diabetes mellitus. Mutat. Res. 554 (2004) 297-304
9. Evans M.D., and Cooke M.S. Factors contributing to the outcome of oxidative damage to nucleic acids. Bioessays 26 (2004) 533-542
10. Powell C.L., Swenberg J.A., and Rusyn I. Expression of base excision DNA repair genes as a biomarker of oxidative DNA damage. Cancer Lett. 229 (2005) 1-11
11. Lindblad P., Chow W.H., Chan J., Bergstrom A., Wolk A., Gridley G., McLaughlin J.K., Nyren O., and Adami H.O. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 42 (1999) 107-112
12. Bailey C.J., and Turner R.C. Metformin drug therapy. N. Engl. J. Med. 334 (1996) 574-579
13. El-Atat F., McFarlane S.I., and Sowers J.R. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr. Hypertens. Rep. 6 (2004) 215-223
14. Lochhead P.A., Salt I.P., Walker K.S., Hardie D.G., and Sutherland C. 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49 (2000) 896-903
15. Pirwany I.R., Yates R.W., Cameron I.T., and Fleming R. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Hum. Reprod. 14 (1999) 2963-2968
16. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., and Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001) 1167-1174
17. Tanaka Y., Iwamoto H., and Onuma T. Inhibitory effect of metformin on formation of advanced glycation end products. Curr. Ther. Res. 58 (1997) 693-697
18. Arnalich F., Hernanz A., Lopez-Maderuelo D., De la Fuente M., Arnalich F.M., Andres-Mateos E., Fernandez-Capitan C., and Montiel C. Intracellular glutathione deficiency is associated with enhanced nuclear factor-kappaB activation in older non-insulin dependent diabetic patients. Free Radic. Res. 35 (2001) 873-884
19. Onaran I., Guven G.S., Ozdas S.B., Kanigur G., and Vehid S. Metformin does not prevent DNA damage in lymphocytes despite its antioxidant properties against cumene hydroperoxide-induced oxidative stress. Mutat. Res. 611 (2006) 1-8
20. Anisimov V.N., Berstein L.M., Egormin P.A., Piskunova T.S., Popovich I.G., Zabezhinski M.A., Kovalenko I.G., Poroshina T.E., Semenchenko A.V., Provinciali M., Re F., and Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol. 40 (2005) 685-693
21. Schneider M.B., Matsuzaki H., Haorah J., Ulrich A., Standop J., Xian-Zhonbg D., Adrian T.E., and Pour P.M. Prevention of pancreatic cancer in hamsters by metformin. Gastroenterology 120 (2001) 1263-1270
22. Renner H.W., and Munzner H. Mutagenicity of sulphonylureas. Mutat. Res. 77 (1980) 347-355
23. Bedir A., Aliyazicioglu Y., Bilgici B., Yurdakul Z., Uysal M., Suvaci D.E., Okuyucu A., Kahraman H., Hökelek M., and Alvur M. Assessment of genotoxicity in rats treated with the antidiabetic agent, Pioglitazone. Environ. Mol. Mutagen. 49 (2008) 185-191
24. Bedir A., Aliyazicioglu Y., Kahraman H., Yurdakul Z., Uysal M., Suvaci D.E., Okuyucu A., Hökelek M., and Alvur M. Genotoxicity in rats treated with the antidiabetic agent, Rosiglitazone. Environ. Mol. Mutagen. 47 (2006) 718-724
25. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 50 (2001) 536-546
26. Baynes J.W., and Thorpe S.R. The role of oxidative stress in diabetic complications. Curr. Opin. Endocrinol. 3 (1997) 277-284
27. Bell Jr. R.H., and Hye R.J. Animal models of diabetes mellitus: physiology and pathology. J. Surg. Res. 35 (1983) 433-460
28. Mendez J.D., and Ramos H.G. Animal models in diabetes research. Arch. Med. Res. 25 (1994) 367-375
29. Adler I.-D. Cytogenetic tests in mammals. In: Venitt S., and Parry J.M. (Eds). Mutagenicity Testing: a Practical Approach (1984), IRL Press, Oxford 275-306
30. Attia S.M. Abatement by naringin of lomefloxacin-induced genomic instability in mice. Mutagenesis 23 (2008) 515-521
31. Wyrobek A.J., and Bruce W.R. Chemical induction of sperm abnormalities in mice. Proc. Natl. Acad. Sci. U.S.A. 72 (1975) 4425-4429
32. World Health Organisation. WHO Laboratory Manual for the Examination of Human Semen Samples and Sperm-Cervical Mucus Interaction. 3rd ed. (1992), Press Syndicate of the University of Cambridge, Cambridge, UK 23-27
33. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 74 (1959) 214-226
34. Ohkawa H., Ohishi N., and Yagi K. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 (1979) 351-358
35. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
36. Bolzan A.D., and Bianchi M.S. Genotoxicity of streptozotocin. Mutat. Res. 7690 (2002) 1-14
37. Weiss R.B. Streptozotocin: a review of its pharmacology, efficacy and toxicity. Cancer Treat. Rep. 66 (1982) 427-438
38. Chinnaswamy N., Fairbairn L.J., Laher J., Willington M.A., and Rafferty J.A. Modulation of O6-alkylating agent induced clastogenecity by enhanced DNA repair capacity of bone marrow cells. Mutat. Res. 416 (1998) 1-10
39. Liegibel U., Tinwell H., Callander R.D., Schmezer P., and Ashby J. Clastogenicity to the mouse bone marrow of the mouse germ cell genotoxin streptozotocin. Mutagenesis 7 (1992) 471-474
40. Vikram A., Tripathi D.N., Ramarao P., and Jena G.B. Evaluation of streptozotocin genotoxicity in rats from different ages using the micronucleus assay. Regul. Toxicol. Pharmacol. 49 (2007) 238-244
41. Imaeda A., Kaneko T., Aoki T., Kondo Y., Nakamura N., Nagase H., and Yoshikawa T. Antioxidative effects of fluvastatin and its metabolites against DNA damage in streptozotocin-treated mice. Food Chem. Toxicol. 40 (2002) 1415-1422
42. Davi G., Falco A., and Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid. Redox Signal. 7 (2005) 256-268
43. Farvid M.S., Djalali M., Siassi F., and Farvid S.S. Association of glomerular and tubular dysfunction with glycaemic control, lipid, lipoprotein, apolipoprotein and antioxidant status in type 2 diabetes mellitus. Singapore Med. J. 48 (2007) 840-846
44. Batista-González C.M., Corona-Rivera J.R., Gómez-Meda B.C., Zamora-Perez A.L., Ramos-Ibarra M.L., and Zúñiga-González G. Micronucleated erythrocytes in preterm newborns in relation to maternal pathology. Rev. Biomed. 17 (2006) 11-16
45. Ramos-Remus C., Dorazco-Barragan G., Aceves-Avila F.J., Alcaraz-Lopez F., Fuentes-Ramirez F., Michel-Diaz J., Torres-Bugarin O., Ventura-Aguilar A., and Zuñiga-González G. Genotoxicity assessment using micronuclei assay in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 20 (2002) 208-212
46. Kulkarni P., Ambani L., and Bhandarkar S. Chromosomal studied in diabetic patients treated with chlorpropamide. Food Chem. Toxicol. 23 (1985) 625-628
47. Martínez-Pérez L.M., Cerda-Flores R.M., Gallegos-Cabriales E.C., Dávila-Rodríguez M.I., Ibarra-Costilla E., and Cortés-Gutiérrez E.I. Frequency of micronuclei in Mexicans with type 2 diabetes mellitus. Prague Med. Rep. 108 (2007) 248-255
48. Sardas S., Yitmaz M., Oztak U., Cakir N., and Karakaya A. Assessment of DNA strand breakage by comet assay in diabetic patients and the role of antioxidant supplementation. Mutat. Res. 490 (2001) 123-129
49. Anderson D., Yutw S., Wright J., and Ioanides C. An examination of DNA strand breakage in the comet assay and antioxidant capacity in diabetic patients. Mutat. Res. 398 (1998) 151-161
50. Hannon-Fletcher M.P.A., ÓKane M.J., Moles K.W., Weatherup C., Barnett C.R., and Barnett Y.A. Levels of peripheral blood cell DNA damage in insulin dependent diabetes mellitus human subjects. Mutat. Res. 460 (2000) 58-60
51. Bonassi S., Hagmar L., Stromberg U., Montagud A.H., Tinnerberg H., Forni A., Heikkila P., Wanders S., Wilhardt P., Hansteen I.L., Knudsen L.E., and Norppa H. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res. 15 (2000) 1619-1625
52. Breza J. Diagnosis and treatment of erectile dysfunctions. Bratisl. Lek. Listy. 96 (1995) 642-650
53. Amaral S., Oliveira P.J., and Ramalho-Santos J. Diabetes and the impairment of reproductive function: possible role of mitochondria and reactive oxygen species. Curr. Diabetes Rev. 4 (2008) 46-54
54. Paz G., and Homonnai Z.T. Leydig cell function in streptozotocin-induced diabetic rats. Experientia 35 (1979) 1412-1413
55. Sexton W.J., and Jarrow J.P. Effect of diabetes mellitus upon male reproductive function. Urology 49 (1997) 508-513
56. Tanaka M., Nakaya S., Kumai T., Watanabe M., Matsumoto N., and Kobayashi S. Impaired testicular function in rats with diet-induced hypercholesterolemia and/or streptozotocin-induced diabetes mellitus. Endocrinol. Res. 27 (2001) 109-117
57. Shrilatha B., and Muralidhara. Early oxidative stress in testis and epididymal sperm in streptozotocin-induced diabetic mice: its progression and genotoxic consequences. Reprod. Toxicol. 23 (2007) 578-587
58. Mossman B.T., Ireland C.M., Filipak M., LeDoux S., and Wilson G.L. Comparative interactions of streptozotocin and chlorozotocin with DNA of an insulin-secreting cell line (RINr). Diabetologia 29 (1986) 186-191
59. Pettepher C.C., LeDoux S.P., Bohr V.A., and Wilson G.L. Repair of alkali-labile sites within the mitochondrial DNA of RINr 38 cells after exposure to the nitrosourea streptozotocin. J. Biol. Chem. 266 (1991) 3113-3117
60. Junod A., Lambert A.E., Stauffacher W., and Renold A.E. Diabetogenic action of streptozotocin: relationship of dose of metabolic response. J. Clin. Invest. 48 (1969) 2129-2139
61. Xu G.W., Yao Q.H., Weng Q.F., Su B.L., Zhang X., and Xiong J.H. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. J. Pharm. Biomed. Anal. 36 (2004) 101-104
62. Aleisa A.M., Al-Rejaie S.S., Bakheet S.A., Al-Bekari A.M., Al-Shabanah O.A., Al-Majed A., Al-Yahya A.A., and Qureshi S. Effect of metformin on clastogenic and biochemical changes induced by adriamycin in Swiss albino mice. Mutat. Res. 634 (2007) 93-100
63. Garcia-Sagredo J.M. Fifty years of cytogenetics: a parallel view of the evolution of cytogenetics and genotoxicology. Biochim. Biophys. Acta 1779 (2008) 363-375
64. Ames B.N. Dietary carcinogens and anticarcinogens, oxygen radicals and degenerative diseases. Science 221 (1983) 1256-1264
65. López-Lázaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol. Nutr. Food Res. 52 Suppl. 1 (2008) S103-S127
66. Bonnefont-Rousselot D., Raji B., Walrand S., Gardes-Albert M., Jore D., Legrand A., Peynet J., and Vasson M.P. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 52 (2003) 586-589
67. Wang S., Kotamraju S., Konorev E., Kalivendi S., Joseph J., and Kalyanaraman B. Activation of nuclear factor-kB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem. J. 367 (2002) 729-740
68. Ferguson L.R., Philpott M., and Karunasinghe N. Dietary cancer and prevention using antimutagens. Toxicology 198 (2004) 147-159
69. De Flora S., and Ferguson L.R. Overview of mechanisms of cancer chemopreventive agents. Mutat. Res. 591 (2005) 8-15